Health Canada Approves BAVENCIO™ (Avelumab for Injection) for the Treatment of Metastatic Merkel Cell Carcinoma (MCC) in Previously Treated Adult Patients

February 22, 2018



Publication Date

February 22, 2018


Samantha Ouimet of EMD Serono


MISSISSAUGA, ON, Feb. 22, 2018 /CNW/ – EMD Serono, Canada, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, and Pfizer Canada Inc. announced that Health Canada has approved BAVENCIO™ (avelumab for injection) for the treatment of metastatic Merkel cell carcinoma (MCC) in previously treated adults. Reviewed under Health Canada’s accelerated approval framework, BAVENCIO was granted a Notice of Compliance with Conditions (NOC/c) based on tumour response and durability of response on December 18, 2017. BAVENCIO, a fully human anti-PD-L1 antibody, is the first Health Canada approved treatment for patients with metastatic MCC, a rare and aggressive type of skin cancer.

View the article